Drug Discovery Alliance
With technology in a constant state of change, transforming one industry after another in its wake, no company can afford to hang on to the status quo for long. But neither can it predict with assurance which promising piece of technology will pan out, spinning off tomorrow’s hot new product. Alliances are the places to hedge all bets.

Libo Pharma Corp. is looking for the highly potential asset, the project which is in the good shape at pre-IND/clinical stage. Libo will be an join co-development partner to accelerate drug development.
Running Under Stealth Mode
Instead of keeping highly potential asset under wraps, Libo Pharma corp. keeps early stage assets go into “permanent stealth mode” to avoid alerting competitors to a pending product launch or another business initiative.
  • Keep as secrete as possible until its time to release
  • Sign partnerships with pharmaceutical companies.
  • Seemingly out of nowhere, hand consumers and investors a finished product or service.

Main Interest

Oncology & Hematology
Novel cancer therapeutics to improve and extend the lives of patients, eg. immuno-oncology, antibody-drug conjugate, and etc.
Immune Disorder
To treat the dysfunction of the immune system with immunomodulator, eg. Diabetics, GVHD and etc.
Regenerative Medicines
Restore structure and function of damaged tissues, eg. wound healing, diabetic foot ulcer, chronic kidney disease and etc.